TerminatedPhase 3NCT03836716
Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial
Studying Amyotrophic lateral sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ZevraDenmark
- Principal Investigator
- Michael Benatar, MD PhDUniversity of Miami
- Intervention
- Arimoclomol(drug)
- Enrollment
- 120 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2021
Study locations (23)
- St. Joseph's Hospital and Medical Center (SJHMC) - Barrow Neurological Institute (BNI) - The Gregory W. Fulton ALS and Neuromuscular Disease Center, Phoenix, Arizona, United States
- UC Irvine Health ALS and Neuromuscular Center, Orange, California, United States
- University of Miami, Miami, Florida, United States
- Hospital for Special Surgery, New York, New York, United States
- Providence Brain & Spine Institute, Portland, Oregon, United States
- University of Pensylvania, Perelman Center for Advanced Medicine - Penn Neuroscience Center, Philadelphia, Pennsylvania, United States
- University of Virginia Health System, Charlottesville, Virginia, United States
- Catholic University Leuven, Leuven, Belgium
- London Health Sciences Centre, London, Ontario, Canada
- Centre Hospitalier Regional Universitaire (CHRU) Montpellier - Hopital Gui De Chauliac, Montpellier, France
- Groupe Hospitalier Pitie-Salpetriere - Centre d'Investigation Clinique Neurosciences 1422, Paris, France
- Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK) - Ambulanz fuer ALS und andere Motoneuronenerkrankungen, Berlin, Germany
- Medizinische Hochschule Hannover (MHH) - Klinik fuer Neurologie, Hanover, Germany
- Universitaetsklinikum Ulm - Klinik fuer Neurologie, Ulm, Germany
- Instituti Clinica Scientifici Maugeri, Milan, Italy
- +8 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03836716 on ClinicalTrials.govOther trials for Amyotrophic lateral sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07401186Stimulation-Based Modulation of Spinal and Cortical Sensory PathwaysPeter C. Gerszten, MD
- RECRUITINGNCT07467187Invasive Home Ventilation in DenmarkRigshospitalet, Denmark
- RECRUITINGNCT07259980A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)Biogen
- RECRUITINGNCT07502677Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral SclerosisRoyal Brompton & Harefield NHS Foundation Trust
- RECRUITINGNANCT07446114Functional Outcomes and Control Using Synchron BCI - CanadaSynchron, Inc.
- ENROLLING BY INVITATIONPHASE2, PHASE3NCT07410806HEALEY ALS Platform Trial - Regimen I NUZ-001Merit E. Cudkowicz, MD
- ENROLLING BY INVITATIONNANCT07298486Impact of Robotic Glove Use on Quality of Life, Grip Strength and Fine Motor Control in ALSNova Southeastern University
- ACTIVE NOT RECRUITINGPHASE1NCT07204977Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)National Institute of Neurological Disorders and Stroke (NINDS)